These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 35401877)
1. Liang L; Yan B; Liu Y; Jiang S; He H; Huang J; Liu W; Xie L Dis Markers; 2022; 2022():4534080. PubMed ID: 35401877 [TBL] [Abstract][Full Text] [Related]
2. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
3. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
4. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling. Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364 [TBL] [Abstract][Full Text] [Related]
5. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
6. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma. Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164 [TBL] [Abstract][Full Text] [Related]
7. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935 [TBL] [Abstract][Full Text] [Related]
8. p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme. Meng J; Qian W; Yang Z; Gong L; Xu D; Huang H; Jiang X; Pu Z; Yin Y; Zou J BMC Cancer; 2024 Mar; 24(1):317. PubMed ID: 38454344 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036 [TBL] [Abstract][Full Text] [Related]
10. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma. Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568 [No Abstract] [Full Text] [Related]
11. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
12. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
13. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577 [TBL] [Abstract][Full Text] [Related]
14. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849 [TBL] [Abstract][Full Text] [Related]
15. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
17. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. Wang J; Li T; Wang B Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448 [TBL] [Abstract][Full Text] [Related]
18. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8 Liu F; Zhou Q; Jiang HF; Zhang TT; Miao C; Xu XH; Wu JX; Yin SL; Xu SJ; Peng JY; Gao PP; Cao X; Pan F; He X; Chen XQ J Exp Clin Cancer Res; 2023 May; 42(1):118. PubMed ID: 37161450 [TBL] [Abstract][Full Text] [Related]
19. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. Wang S; Chen C; Li J; Xu X; Chen W; Li F J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273 [TBL] [Abstract][Full Text] [Related]
20. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]